Journal article
Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial
Abstract
BackgroundSingle nucleotide polymorphisms (SNPs) in the estrogen receptor 1 (ESR1) and cytochrome P450 19A1 (CYP19A1) genes have been associated with breast cancer risk, endocrine therapy response and side effects, mainly in postmenopausal women with early breast cancer. This analysis aimed to assess the association of selected germline CYP19A1 and ESR1 SNPs with early-onset hot flashes, sweating and musculoskeletal symptoms in premenopausal …
Authors
Johansson H; Gray KP; Pagani O; Regan MM; Viale G; Aristarco V; Macis D; Puccio A; Roux S; Maibach R
Journal
Breast Cancer Research, Vol. 18, No. 1,
Publisher
Springer Nature
Publication Date
12 2016
DOI
10.1186/s13058-016-0771-8
ISSN
1465-5411
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdultAgedAntineoplastic Combined Chemotherapy ProtocolsAromataseBreast NeoplasmsClinical Trials, Phase III as TopicDrug-Related Side Effects and Adverse ReactionsEstrogen Receptor alphaFemaleGenetic VariationHot FlashesHumansMiddle AgedOdds RatioPharmacogenomic VariantsRandomized Controlled Trials as TopicRisk FactorsSweating